Blinding Onchocerciasis in Pader District, Northern Uganda
Background: Onchocerciasis is caused by a filarial nematode Onchocerca volvulus, and is transmitted by a female black fly of the genus Simulium which breeds in fast flowing rivers. In Uganda, the disease is endemic in 37 districts with clinical manifestations mainly on the skin. The long-term armed conflict in northern Uganda made research and control of onchocerciasis in the region and particularly Pader district receive little attention. There have been no attempts to establish the magnitude of the disease in the region.
Objective: To establish the magnitude and clinical manifestations of Onchocerciasis in Pader district, northern Uganda.
Methods: Twenty parishes in sub counties with Rapid Epidemiological Mapping of Onchocerciasis (REMO) nodule prevalence of 25.0% or more were randomly sampled and 675 persons consecutively enrolled in 13 parishes. The respondents underwent dermatological, parasitological and ocular examinations.
Results: A total of 675 persons were examined and of these, 318 had skin snipping and microscopy done. The prevalence of microfilaria (mf) in skin snip was 29.6% (95% CI: 24.6%-34.6%) while prevalence of nodules was 30.1% (95% CI: 3.1%-6.5%). The prevalence of microfilaria in the anterior chamber of the eye (MFAC) was 4.1% (95% CI: 2.6%-5.6%) and that of reversible ocular lesions was 4.0% (95% CI: 2.5%-5.5%). The reversible ocular lesions of onchocerciasis observed were punctate keratitis stage B (PKB, 0.1%), punctate keratitis stage D (PKD, 0.1%) and punctate keratitis stage E (PKE, 3.7%) while the irreversible ocular lesions were observed in 16.1% (95% CI: 13.3%-18.9%) of the respondents. The most important irreversible lesions were optic atrophy 6.4%, (95% CI: 3.7%-9.1%) and sclerosing keratitis, 5.2% (95% CI: 2.8%-7.6%). Visual impairment was detected in 29.2% (95% CI: 25.8%-32.6%) of the respondents and the main causes were cataracts (27.4%) and optic atrophy (21.8%). The association between irreversible lesion and visual loss (p< 0.00) and irreversible lesions and nodules (p< 0.00) were both significant.Conclusion: This study indicates that the onchocerciasis in Pader district is the blinding type. There is need to strengthen health education, community social mobilization and start biannual Mass Drug Administration (MDA) with Ivermectin.
WHO (1995). Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis, Technical Report Series, No. 852, Geneva:WHO.
Ndyomugyenyi, R. The burden of onchocerciasis in Uganda. Ann. Trop. Med. Parasit. 1998; 92:S133-S137.
Watmon B (2007). Onchocerciasis in Aruu County Pader District; Report on Onchocerciasis seen during Eye Camps at Awere Health Centre III and Lacekocot Health Centre III, Pader District [Un- Published data].
Kish, L, Frankel, MR. Inference from complex samples. J Royal Statistical Society, Series B. 1974; 36: 1 – 37.
Bennet S, Words T, Liyange WM, Smith D. Simplified general methods for cluster sample surveys in developing countries. Quart. 1991; 44: 98-106.
Lakwo TL, Tukesiga E, Katongole C, Komakech JB, Oyet S, Odonga P. (2008). Report on the Rapid Epidemiological Mapping of Onchocerciasis in Kitgum and Pader districts, Northern Uganda. (Unpublished document).
Gilbert C, Foster A, Negrel AD, Thylefors B. Childhood blindness. A new form for recording causes of visual loss in children. Bull. WHO. 1993; 71 (5): 485-489.
Katabarwa M, Eyamba A, Habomugisha P, Lakwo TL, Ekobo S, et al. After a decade of annual mass ivermectin treatment in Cameroon and Uganda, Onchocerciasis transmission continues. Trop Med Intern Health; 2008; 13: 1196 -1203.
Fischer P, Kipp W, Bamuhiga J, Binta-Kahwa J, Kiefer A, Buttner DW. Parasitological and clinical characterization of S. Neavei transmitted onchocerciasis in western Uganda. Trop. Med. Parasit. 1993; 44: 311-321.
Krupp MA, Chatton MJ. Current medical diagnosis and treatment. Large Medical Publications. 1978; 94022: 892-893.
Newland HS, White AT, Greene BM, Murphy RP, Taylor HR. Ocular manifestations of onchocerciasis in a rain forest area of West Africa. Ophthalmol. 1991; 75(3): 163 - 169.
Abiose, A. Onchocercal eye disease and impact of Mectizan treatment. Annals Trop Med Parasitol. 1998; 92: S11-S22.
Dadzie KY, Remme J, Alley ES, De Sole G, Changes in ocular onchocerciasis four and twelve months after community-based treatment with ivermectin in a holoendemic onchocerciasis focus. Trans. Roy. Soc. Trop. Med. Hyg. 1990a; 84: 103-108.
Kirk R. Factors in the pathogenesis of ocular onchocerciasis. Bull. WHO. 1957; 16: 485-493.
Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, et al. Reduction in the incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993; i: 130-134.
Berghout, E. Onchocerciasis and optic atrophy in the savannah area of Ghana. Trop Geog. Med. 1987; 39:323-329.
Ukety T, Nyathirombo A, Watmon B, Habomugisha P (2007). Evaluation of Onchocerciasis treatment in eight sentinel villages in Adjumani and Moyo districts, Uganda. (Unpublished document).
Fuglsang H, Anderson J. In: WHO (1987) Expert Committee on Onchocerciasis. World Health. Organisation. Technical Report series. 752, pp. 66.
Ogunrinade A, Boakye D, Merriweather A, TR. Unnasch. Distribution of blinding and non blinding onchocerca volvulus in Nigeria. http://www.jstor.org
Kocur Ivo. What is new at the back of the eye? Comm Eye Health. 2006; 19; (57); 1-3.